Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luxerm Daylight PDT for Actinic Keratosis – Subject-Reported Outcomes
2017-000066-29Phase 4Completed
- Sponsor
- Galderma
- Start
- Mar 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methyl aminolevulinate in actinic keratosis (AK), sponsored by Galderma. Primary endpoint: Subject-reported outcomes on satisfaction, efficacy and safety. Started Mar 2017; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2017-000066-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000066-29.